Sameem Abedin, MD

Assistant Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Bengali

Contact Information

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Sameem Abedin, MD, is an Assistant Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology. His specialization is in leukemia and stem cell transplantation at Froedtert Hospital. He obtained his undergraduate degree at the University of Pennsylvania, PA, in 2004, and his medical degree at Jefferson Medical College in 2009. He completed his residency in Internal Medicine at the University of Pittsburgh Medical Center in Pittsburgh, PA, in 2012. In 2017, he then completed his fellowship in Hematology and Oncology at Northwestern University in Chicago, IL, where he also served as Chief Fellow. His current clinical and research interests include patients with acute leukemia, including AML and ALL, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), chronic myeloid leukemia (CML), and allogeneic stem cell transplantation for these conditions. His professional memberships include the American Society of Hematology and the American Society of Bone Marrow Transplantation.

Dr. Abedin is board certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, and in Hematology and Medical Oncology.

Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.

(Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS.) Leuk Lymphoma. 2020 Sep 19:1-9 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020
Letter to the Editor Regarding Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, Shaw BE.) Biol Blood Marrow Transplant. 2020 09;26(9):e241-e242 PMID: 32589922 PMCID: PMC7309826 SCOPUS ID: 2-s2.0-85087728830 06/27/2020
Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation.

(Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S.) Biol Blood Marrow Transplant. 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.

(George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L.) Leuk Res. 2020 07;94:106368 PMID: 32442786 SCOPUS ID: 2-s2.0-85084755644 05/23/2020
Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.

(Abedin SM, Hamadani M.) Expert Opin Investig Drugs. 2020 May;29(5):423-427 PMID: 32293938 SCOPUS ID: 2-s2.0-85083651597 04/16/2020
Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database.

(Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E.) J Natl Compr Canc Netw. 2020 02;18(2):169-175 PMID: 32023530 SCOPUS ID: 2-s2.0-85079065513 02/06/2020
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study

(George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L.) Leukemia Research. July 2020;94 SCOPUS ID: 2-s2.0-85084755644 07/01/2020
Inhibitory effects of SEL201 in acute myeloid leukemia.

(Kosciuczuk EM, Kar AK, Blyth GT, Fischietti M, Abedin S, Mina AA, Siliezar R, Rzymski T, Brzozka K, Eklund EA, Beauchamp EM, Eckerdt F, Saleiro D, Platanias LC.) Oncotarget. 2019 Dec 24;10(67):7112-7121 PMID: 31903169 PMCID: PMC6935253 01/07/2020
Natural killer cell activity and survival after azacitidine treatment in high-risk MDS.

(Abedin SM, Platanias LC.) Leuk Lymphoma. 2019 10;60(10):2343-2344 PMID: 31120354 SCOPUS ID: 2-s2.0-85066879883 05/24/2019
Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

(Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2019 08;25(8):1689-1694 PMID: 30965140 SCOPUS ID: 2-s2.0-85065022222 04/10/2019
Myeloid malignancies after treatment for solid tumours.

(Guru Murthy GS, Abedin S.) Best Pract Res Clin Haematol. 2019 03;32(1):40-46 PMID: 30927974 SCOPUS ID: 2-s2.0-85062663467 04/01/2019